GARCIA RUBEN A
Known title: General CounselCIK: 0002013617
GARCIA RUBEN A's purchase track record
GARCIA RUBEN A has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/27/2026 | FBLG | $13K | -82.4% | -78.1% | +12.1% |
| 12/11/2025 | FBLG | $48K | -2.3% | -86.2% | +7.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FBLG | ▲ Buy | Open Market | 40,000 | $13K | 2/27/2026 | View on chart |
| FBLG | ▲ Buy | Open Market | 140,000 | $48K | 12/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
FibroBiologics Secures European Patent for Fibroblast Methods
FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.
FibroBiologics Secures European Patent for Fibroblast Methods. FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.